Plasma levels of procalcitonin and eight additional inflammatory molecules in febrile neutropenic patients

Clinics

Volumn 66, Issue 10, 2011, Pages 1699-1705

  Neuenschwander, Letícia Carvalho ^a   Bittencourt, Henrique ^a   Ribeiro, Ana Flávia Tibúrcio ^a   Teixeira, Antônio Lúcio ^a   Teixeira, Mauro M ^a   Teixeira, Jairo Cerqueira ^a   Nobre, Vandack ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Febrile neutropenia; Inflammatory markers; Procalcitonin; Sensitivity; Specificity

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCITONIN; EOTAXIN; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCALCITONIN; PROTEIN PRECURSOR; TNFRSF1A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; ARTICLE; BLOOD; CAUSE OF DEATH; EPIDEMIOLOGY; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NEUTROPENIA; PROSPECTIVE STUDY; TIME;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CAUSE OF DEATH; CHEMOKINE CCL11; CHEMOKINE CCL2; CHEMOKINE CCL3; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054723777     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011001000006     Document Type: Article

References (32)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-40.
2. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284:1061-5, doi: 10.1056/NEJM197105132841904.
3. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-51, doi: 10.1086/339215.
4. Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H, et al. Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer. 1994;30A:430-7, doi: 10.1016/0959-8049(94)90412-X.
5. Anaissie EJ, Vadhan-Raj S. Is it time to redefine the management of febrile neutropenia in cancer patients? Am J Med. 1995;98:221-3, doi: 10.1016/S0002-9343(99)80366-0.
6. Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999;341:305-11, doi: 10.1056/NEJM199907293410501.
7. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1999;341:312-8, doi: 10.1056/NEJM199907293410502.
8. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988;148: 2561-8.
9. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10:316-22.
10. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-51.
11. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000;89:523-33, doi: 10.1002/1097-0142(20000801)89:3<523::AID-CNCR7>3.0.CO;2-6.
12. Buyukberber N, Buyukberber S, Sevinc A, Camci C. Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients. Med Oncol. 2009;26:55-61, doi: 10.1007/s12032-008-9081-z.
13. Persson L, Engervall P, Magnuson A, Vikerfors T, Soderquist B, Hansson LO, et al. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis. 2004;36:365-71, doi: 10.1080/00365540410020217.
14. Kern WV, Heiss M, Steinbach G. Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis. 2001;32:832-5, doi: 10.1086/319207.
15. de Bont ES, Vellenga E, Swaanenburg JC, Fidler V, Visser-van Brummen PJ, Kamps WA. Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol. 1999;107:375-80, doi: 10.1046/j.1365-2141.1999.01707.x.
16. Ellis M. Febrile neutropenia. Ann N Y Acad Sci. 2008 Sep; 1138:329-50, doi: 10.1196/annals.1414.035.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83, doi: 10.1016/0021-9681(87)90171-8.
18. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55, doi: 10.1097/00000421-198212000-00014.
19. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med. 2003;138:40-4.
20. de Bont ES, Vellenga E, Swaanenburg J, Kamps W. Procalcitonin: a diagnostic marker of bacterial infection in neutropenic cancer patients with fever? Infection. 2000;28:398-400, doi: 10.1007/s150100070014.
21. Lehrnbecher T, Groll AH, Chanock SJ. Treatment of fungal infections in neutropenic children. Curr Opin Pediatr. 1999;11:47-55, doi: 10.1097/00008480-199902000-00010.
22. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis. 2004;23:539-44.
23. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med. 1994;45:491-503, doi: 10.1146/annurev.med.45.1.491.
24. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5:392-9, doi: 10.1016/S0962-8924(00)89088-1.
25. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36:941-52, doi: 10.1097/CCM.0B013E318165BABB.
26. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164:396-402.
27. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in communityacquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174:84-93, doi: 10.1164/rccm.200512-1922OC.
28. Persson L, Soderquist B, Engervall P, Vikerfors T, Hansson LO, Tidefelt U. Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol. 2005;74:297-303, doi: 10.1111/j.1600-0609.2004.00387.x.
29. Massaro KS, Costa SF, Leone C, Chamone DA. Procalcitonin (PCT) and Creactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis. 2007;7:137, doi: 10.1186/1471-2334-7-137.
30. Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, Galani L, Anagnostopoulos N, Grecka P, et al. Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect. 2004;10:628-33, doi: 10.1111/j.1469-0691.2004.00883.x.
31. Zimmermann N, Hershey GK, Foster PS, Rothenberg ME. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol. 2003;111:227-42; quiz 43, doi: 10.1067/mai. 2003.139.
32. Menzies-Gow A, Ying S, Sabroe I, Stubbs VL, Soler D, Williams TJ, et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol. 2002;169:2712-8.